Your browser doesn't support javascript.
loading
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson, Laurence B; Bell, Charles J M; Howlett, Sarah K; Pekalski, Marcin L; Brady, Kevin; Hinton, Heather; Sauter, Denise; Todd, John A; Umana, Pablo; Ast, Oliver; Waldhauer, Inja; Freimoser-Grundschober, Anne; Moessner, Ekkehard; Klein, Christian; Hosse, Ralf J; Wicker, Linda S.
Affiliation
  • Peterson LB; Roche Innovation Center Basel, Roche Pharma Research & Early Development (pRED), Grenzacherstrasse 124, 4070, Basel, Switzerland; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, NIHR Cambridge Biomedical Research Centr
  • Bell CJM; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, CB2 OXY, UK.
  • Howlett SK; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, CB2 OXY, UK.
  • Pekalski ML; JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute f
  • Brady K; Roche Innovation Center Basel, Roche Pharma Research & Early Development (pRED), Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Hinton H; Roche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
  • Sauter D; Roche Innovation Center Basel, Roche Pharma Research & Early Development (pRED), Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Todd JA; JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute f
  • Umana P; Roche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
  • Ast O; Roche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
  • Waldhauer I; Roche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
  • Freimoser-Grundschober A; Roche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
  • Moessner E; Roche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
  • Klein C; Roche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
  • Hosse RJ; Roche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
  • Wicker LS; JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute f
J Autoimmun ; 95: 1-14, 2018 12.
Article in En | MEDLINE | ID: mdl-30446251
Subject(s)
Autoimmune Diseases/therapy; Immunoglobulin G/immunology; Immunotherapy/methods; Interleukin-2/immunology; Lymphotoxin-alpha/immunology; Recombinant Fusion Proteins/immunology; T-Lymphocytes, Regulatory/drug effects; Animals; Autoimmune Diseases/genetics; Autoimmune Diseases/immunology; Autoimmune Diseases/pathology; Binding Sites; CD8-Positive T-Lymphocytes/drug effects; CD8-Positive T-Lymphocytes/immunology; CD8-Positive T-Lymphocytes/pathology; CTLA-4 Antigen/genetics; CTLA-4 Antigen/immunology; Cell Proliferation; DNA Methylation/drug effects; Disease Models, Animal; Epigenesis, Genetic; Forkhead Transcription Factors/genetics; Forkhead Transcription Factors/immunology; Humans; Immunoglobulin G/administration & dosage; Immunoglobulin G/chemistry; Immunoglobulin G/genetics; Interleukin-2/administration & dosage; Interleukin-2/chemistry; Interleukin-2/genetics; Interleukin-2 Receptor beta Subunit/genetics; Interleukin-2 Receptor beta Subunit/immunology; Lymphocyte Activation/drug effects; Lymphotoxin-alpha/administration & dosage; Lymphotoxin-alpha/chemistry; Lymphotoxin-alpha/genetics; Macaca fascicularis; Male; Mice; Mice, Transgenic; Models, Molecular; Protein Binding; Protein Isoforms/genetics; Protein Isoforms/immunology; Protein Structure, Secondary; Recombinant Fusion Proteins/administration & dosage; Recombinant Fusion Proteins/chemistry; Recombinant Fusion Proteins/genetics; STAT5 Transcription Factor/genetics; STAT5 Transcription Factor/immunology; Signal Transduction; T-Lymphocytes, Regulatory/immunology; T-Lymphocytes, Regulatory/pathology
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Recombinant Fusion Proteins / Immunoglobulin G / Interleukin-2 / Lymphotoxin-alpha / T-Lymphocytes, Regulatory / Immunotherapy Type of study: Prognostic_studies Language: En Journal: J Autoimmun Journal subject: ALERGIA E IMUNOLOGIA Year: 2018 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Recombinant Fusion Proteins / Immunoglobulin G / Interleukin-2 / Lymphotoxin-alpha / T-Lymphocytes, Regulatory / Immunotherapy Type of study: Prognostic_studies Language: En Journal: J Autoimmun Journal subject: ALERGIA E IMUNOLOGIA Year: 2018 Document type: Article